

Contents

1 Summary and Policy Options 1




- Introduction and Congressional Request 1
- Focus and Organization of the Report 2
- Summary of Findings 3
- Issues and Options 4
 - Coverage Options 5
 - Options Regarding Sources of Information on Effectiveness and Cost-Effectiveness 8
 - Options Regarding Specific Benefit Design Features 9
 - Access Options 10
 - Research Options 11

2 Overview of the Issues 13

- Defining Clinical Preventive Services 13
- Strengths and Weaknesses of Insurance as a Source of Funding for Preventive Services 14
- Criteria for Evaluating Clinical Preventive Services 15
 - The Role of Evidence on Effectiveness 16
 - The Role of Costs 17
 - Other Criteria 18
- Insurance Benefit Design 18
 - Specifying and Circumscribing the Benefits 19
 - Unit of Payment 21

3 Evidence on the Effectiveness of a Select Group of Clinical Preventive Services 23

- Review of the Evidence 24
 - Annual General Physical Examination 24
 - Breast Cancer Screening 24
 - Colorectal Cancer Screening 27
 - Cervical Cancer Screening 28
 - Prostate Cancer Screening 28
 - Cholesterol Screening 29
 - Hypertension Screening 30
 - Smoking Cessation Interventions 31
 - Adult Immunizations 32



- Prenatal Care **32**
- Newborn Screening for Congenital Disorders 33
- Childhood Immunizations 33
- Well-Child Care 34
 - General Physical Examinations 34
 - Screening for Iron-Deficiency for Anemia 34
 - Screening for Amblyopia and Strabismus 35
 - Screening for Hearing Impairment **35**
 - Developmental Screening **36**
 - Urinalysis 36
 - Frequency of Well-Child Care Services 36
 - Summary 36
- Contraceptive Services 37
- Screening for Sexually Transmitted Diseases 37
- Summary 38

4 The Role of Costs in Benefit Design Decisions 39


- Use of Cost-Effectiveness Analyses in Benefit Design 39
- Net Costs as a Criterion for Insurance Coverage 41
- summary 43

Boxes

- 1-A Other Publications in the Office of Technology Assessment's Series on Benefit Design in Health Care Reform 2
- F-1 Important Concepts for Determining the Efficacy of a Screening Test **80**

Figures

- 1-1 Policy Issues Concerning Insurance Coverage for Clinical Preventive Services 4
- 2-1 Evidence on the Effects of Care: Essential, But Not Sufficient, For Improving Policies and Decisions in Health Care 18
- 2-2 Leading Causes of Death, 1989, All Ages 19
- 2-3 Leading Causes of Years of Potential Life Lost (YPLL) Before Age 65, 1989 20
- E-1 Percent of Enrollees Covered for Well-Baby Care in Employer-Based Health Insurance Plans by Plan Type, Various Surveys, Various Years 74
- E-2 Percent of Enrollees Covered for Well-Child Care in Employer-Based Health Insurance Plans by Plan Type, Various Surveys, Various Years 74



E-3 Percent of Enrollees Covered for Adult Physical Examinations in Employer-Based Health Insurance Plans by Plan Type, Various Surveys, Various Years 75

Tables

- 1-1 Potential Goals of Policies Concerning Insurance for Clinical Preventive Services 5
- 1-2 Policy Options for Congressional Consideration 6
- 3-1 Preventive Interventions Recommended By the U.S. Preventive Services Task Force for Nonpregnant, Asymptomatic Persons, 1989 25
- 3-2 Preventive Interventions Not Recommended By the U.S. Preventive Services Task Force for Use on Asymptomatic Persons, 1989 26
- 3-3 The Number of States Screening for Specific Types of Newborn Congenital Disorders and Number of Cases Confirmed with the Diagnosis, 1990 33
- 4-1 Selected Cost-Effectiveness Analyses of Adult Immunizations 44
- 4-2 Selected Cost-Effectiveness Analyses of Breast Cancer Screening 46
- 4-3 Selected Cost-Effectiveness Analyses of Cervical Cancer Screening 47
- 4-4 Selected Cost-Effectiveness Analyses for Childhood Immunizations 48
- 4-5 Selected Cost-Effectiveness Analyses of Cholesterol Reduction Interventions 51
- 4-6 Selected Cost-Effectiveness Analyses of Colorectal Cancer Screening 53
- 4-7 Selected Cost-Effectiveness Analyses of Hypertension Screening 54
- 4-8 Selected Cost-Effectiveness Analyses of Smoking Cessation 55
- F-1 Institute of Medicine Provisional Documentation Checklist for Practice Guidelines 78
- F-2 Quality of Evidence Criteria Used By the U.S. Preventive Services Task Force and the Canadian Task Force 79
- G-1 Birth to 18 Months (Schedule: 2,4,6, 15, 18 Months) 83
- G-2 Ages 2-6 84
- G-3 Ages 7-12 85
- G-4 Ages 13-18 86
- G-5 Ages 19-39 (Schedule: Every 1-3 Years) 88

- G-6 Ages 40-64 (Schedule: Every 1-3 Years) 91
- G-7 Ages 65 and Over (Schedule: Every Year) 94
- G-8 Pregnant Women 96
- H-1 Clinical Preventive Services Included in or Specifically Excluded from Congressional Health Care Reform Proposals, 102d Congress 99

APPENDIXES

- A Overview of OTA Assessment: Technology, Insurance, and the Health Care System 57**
- B Method of the Study 60**
- c Acknowledgments 61**
- D Abbreviations and Glossary of Terms 63**
- E Current Coverage of Clinical Preventive Health Care Services in Public and Private Insurance 72**
- F Synthesizing and Assessing the Evidence and Determining Practice Policies 77**
- G Summary of the U.S. Preventive Services Task Force's (USPSTF) Recommendations for Services To Be Included in Periodic Health Examinations, by Age Group 82**
- H Preventive Services in Health Care Reform Proposals Introduced in the 102d Congress 98**

REFERENCES 101

INDEX 113